Skip to main content
    P

    Progyny Inc (PGNY)

    Official site

    HEALTHCARE • HEALTHCARE PLANS • NASDAQ

    $36.18
    -0.40 (-1.09%)

    Market Cap: $2.66B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Progyny Inc (PGNY) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Progyny (PGNY) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Progyny reported EPS of $0.31, above the $0.27 estimate. It beat the EPS estimate in each of the last 23 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    93%(28/30)
    Avg Surprise
    +95.78%
    Streak
    23 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.35
    Range$0.30 - $0.40
    14 analysts
    Revenue Consensus
    $362.33M
    Range$334.18M - $380.92M
    13 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.57
    Range$0.55 - $0.61
    5 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.55+4.8%
    60d ago$0.55+4.3%
    30d ago$0.55+4.3%
    7d ago$0.55+3.5%
    Current$0.57
    Revenue Consensus
    $366.82M
    Range$360.77M - $375.30M
    6 analysts

    Next Report

    PGNY has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 150.0% above the $0.14 reported for the quarter ended Dec 31, 2025.

    PGNY Earnings Call

    The latest PGNY earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, PGNY beat 28 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $341.25M, up 8.9% from $313.35M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.31$0.27N/A+14.81%Beat-31.1%91 up, 6 downNov 4, 2026$341.25M
    Jun 30, 2026$0.34$0.28N/A+21.43%Beat+78.9%80 up, 0 downAug 6, 2026$350.51M
    Mar 31, 2026$0.50$0.44$0.43 - $0.45+13.64%Beat+4.2%80 up, 5 downMay 7, 2026$328.50M
    Dec 31, 2025$0.14$0.13N/A+7.69%Beat-66.7%82 up, 0 downFeb 26, 2026$318.40M
    Sep 30, 2025$0.45$0.39$0.38 - $0.40+15.38%Beat+12.5%74 up, 1 downNov 6, 2025$313.35M
    Jun 30, 2025$0.19$0.17N/A+11.76%Beat-55.8%63 up, 0 downAug 7, 2025$332.87M
    Mar 31, 2025$0.48$0.45$0.44 - $0.46+6.67%Beat+23.1%74 up, 0 downMay 8, 2025$324.04M
    Dec 31, 2024$0.42$0.37$0.33 - $0.43+13.51%Beat+223.1%62 up, 0 downFeb 27, 2025$298.43M
    Sep 30, 2024$0.40$0.37N/A+8.11%Beat+150.0%90 up, 0 downNov 12, 2024$286.63M
    Jun 30, 2024$0.43$0.40N/A+7.50%Beat+186.7%100 up, 0 downAug 6, 2024$304.09M
    Mar 31, 2024$0.39$0.35N/A+11.43%Beat+116.7%90 up, 0 downMay 9, 2024$278.08M
    Dec 31, 2023$0.13$0.11$0.07 - $0.19+18.18%Beat+333.3%100 up, 0 downFeb 27, 2024$269.94M
    Sep 30, 2023$0.16$0.11$0.09 - $0.17+45.45%Beat+23.1%70 up, 0 downNov 7, 2023$280.89M
    Jun 30, 2023$0.15$0.10$0.09 - $0.14+50.00%Beat+66.7%70 up, 0 downAug 3, 2023$279.37M
    Mar 31, 2023$0.18$0.08$0.06 - $0.08+125.00%Beat+260.0%61 up, 0 downMay 8, 2023$258.39M
    Dec 31, 2022$0.03$0.01-$0.03 - $0.03+200.00%Beat-80.0%60 up, 1 downFeb 27, 2023$214.32M
    Sep 30, 2022$0.13$0.03$0.01 - $0.15+333.33%Beat-23.5%70 up, 0 downNov 3, 2022$205.37M
    Jun 30, 2022$0.09$0.01N/A+800.00%Beat-52.6%N/A0 up, 0 downAug 4, 2022$195.00M
    Mar 31, 2022$0.05-$0.02-$0.02 - $0.10+350.00%Beat-66.7%50 up, 0 downMay 5, 2022$172.22M
    Dec 31, 2021$0.15$0.04$0.02 - $0.07+275.00%Beat+1400.0%50 up, 1 downFeb 28, 2022$127.55M
    Sep 30, 2021$0.17$0.06$0.05 - $0.08+183.33%Beat+142.9%5N/ANov 4, 2021$122.28M
    Jun 30, 2021$0.19$0.09$0.08 - $0.09+111.11%BeatN/A3N/AAug 5, 2021$128.65M
    Mar 31, 2021$0.15$0.09N/A+66.67%Beat+200.0%3N/AMay 6, 2021$122.13M
    Dec 31, 2020$0.01$0.06$0.05 - $0.06-83.33%Miss0.0%3N/AFeb 24, 2021$100.30M
    Sep 30, 2020$0.07$0.06$0.04 - $0.06+16.67%Beat+133.3%5N/ANov 5, 2020$98.93M
    Jun 30, 2020-$0.01-$0.02-$0.05 - -$0.01+50.00%Beat-133.3%5N/AAug 5, 2020$64.61M
    Mar 31, 2020$0.05$0.02-$0.01 - $0.06+150.00%BeatN/A4N/AMay 12, 2020$81.02M
    Dec 31, 2019$0.01$0.02$0.01 - $0.06-50.00%MissN/A4N/AMar 5, 2020$65.12M
    Sep 30, 2019$0.03$0.02$0.02 - $0.02+50.00%BeatN/A4N/AOct 25, 2019$61.20M
    Jun 30, 2019$0.03$0.02N/A+50.00%BeatN/AN/AN/AAug 2, 2019$56.17M
    Last 30 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.26, down 23.2% from the year before. It was $0.07 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.26-23.2%
    Dec 31, 2024$1.64+164.5%
    Dec 31, 2023$0.62+106.7%
    Dec 31, 2022$0.30-54.5%
    Dec 31, 2021$0.66+450.0%
    Dec 31, 2020$0.12+71.4%
    Dec 31, 2019$0.07N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,44814
    2026Q2Jun 30, 20265,72713
    2026Q1Mar 31, 20265,95812
    2025Q4Dec 31, 20256,74512
    2025Q3Sep 30, 20255,58712
    2025Q2Jun 30, 20255,90712
    2025Q1Mar 31, 20255,11610
    2024Q4Dec 31, 20246,91814

    2026Q3 Earnings Call

    Opening remarks

    James Hart Host Thank you, Sylvie, and good afternoon, everyone. Welcome to our third quarter conference call. With me today are Pete Anevski, CEO of Progyny, and Mark Livingston, CFO. We will begin with some prepared remarks before we open the call for your questions. Before we begin, I'd like to remind you that our comments and responses to your questions today reflect management's views as of today only and will include statements related to our financial outlook for both the fourth quarter and full year 2026 and the assumptions and drivers underlying such guidance; the demand for our solutions; our expectations for our selling season for 2027 launches; anticipated employment levels of our clients and the industries we serve; the timing of client decisions; our expected utilization rates and mix; the potential benefits of our solution; our ability to acquire new clients and retain and upsell existing clients; our market opportunity and our business strategy, plans, goals and expectations concerning our market position, future operations and other financial and operating information, which are forward-looking statements under the federal securities law. Actual results may differ materially from those contained in or implied by these forward-looking statements due to risks and uncertainties associated with our business as well as other important factors. For a discussion of the material risks, uncertainties, assumptions and other important factors that could impact our actual results, please refer to our SEC filings and today's press release, both of which can be found on our Investor Relations website. Any forward-looking statements that we make on this call are based on assumptions as of today, and we undertake no obligation to update these statements as a result of new information or future events. During the call, we will also refer to non-GAAP financial measures, such as adjusted EBITDA. More information about these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, is available in the press release, which is available at investors.progyny.com. I would now like to turn the call over to Pete.

    Peter Anevski CEO Thanks, Jamie, and thanks, everyone, for joining us this afternoon. I'm pleased to report that Progyny had a strong quarter, resulting in record revenue and profitability for the third quarter as well as the continued generation of significant cash flow, which we're using both to invest in the business for future growth and return value to our shareholders through meaningful share repurchase activity. As the fourth quarter begins, member engagement remains healthy. Given that, as well as our strong performance over the first nine months of the year, we're pleased to be in a position to raise the midpoint of our full-year guidance.

    Frequently Asked Questions About PGNY

    When is Progyny's next earnings date?

    Progyny's next earnings report is expected for Feb 24, 2027.

    Did PGNY beat earnings estimates last quarter?

    Yes. Progyny reported EPS of $0.31 for the quarter ended Sep 30, 2026, above the $0.27 estimate, a 14.81% surprise.

    What EPS do analysts expect from PGNY next quarter?

    The consensus EPS estimate for Progyny for the quarter ending Dec 31, 2026 is $0.35 from 14 analysts, with estimates from $0.30 to $0.40.

    How often does PGNY beat earnings estimates?

    Progyny beat the EPS estimate in each of the last 23 quarters, with an average surprise of +116.96%.